Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
7.20
-0.11 (-1.50%)
Jan 28, 2026, 2:29 PM EST - Market open
Verrica Pharmaceuticals Revenue
Verrica Pharmaceuticals had revenue of $14.34M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $30.83M, up 234.73% year-over-year. In the year 2024, Verrica Pharmaceuticals had annual revenue of $7.57M with 47.66% growth.
Revenue (ttm)
$30.83M
Revenue Growth
+234.73%
P/S Ratio
2.09
Revenue / Employee
$434,211
Employees
71
Market Cap
115.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.57M | 2.44M | 47.66% |
| Dec 31, 2023 | 5.12M | -3.91M | -43.27% |
| Dec 31, 2022 | 9.03M | -2.97M | -24.73% |
| Dec 31, 2021 | 12.00M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 127.63M |
| Agenus | 106.83M |
| Fortress Biotech | 62.30M |
| Seer, Inc. | 16.38M |
| Repare Therapeutics | 11.87M |
| Artiva Biotherapeutics | 251.00K |
| Adagene | 103.20K |
VRCA News
- 21 days ago - Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals Inc. (VRCA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting - GlobeNewsWire
- 3 months ago - Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 3 months ago - Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union - GlobeNewsWire
- 4 months ago - Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire